Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 1;19(6):1642.
doi: 10.3390/ijms19061642.

VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications

Khaled R Alkharsah  1
Affiliations
Review

VEGF Upregulation in Viral Infections and Its Possible Therapeutic Implications

Khaled R Alkharsah. Int J Mol Sci. .

Abstract

Several viruses are recognized as the direct or indirect causative agents of human tumors and other severe human diseases. Vascular endothelial growth factor (VEGF) is identified as a principal proangiogenic factor that enhances the production of new blood vessels from existing vascular network. Therefore, oncogenic viruses such as Kaposi's sarcoma herpesvirus (KSHV) and Epstein-Barr virus (EBV) and non-oncogenic viruses such as herpes simplex virus (HSV-1) and dengue virus, which lack their own angiogenic factors, rely on the recruitment of cellular genes for angiogenesis in tumor progression or disease pathogenesis. This review summarizes how human viruses exploit the cellular signaling machinery to upregulate the expression of VEGF and benefit from its physiological functions for their own pathogenesis. Understanding the interplay between viruses and VEGF upregulation will pave the way to design targeted and effective therapeutic approaches for viral oncogenesis and severe diseases.

Keywords: Dengue fever virus; Epstein-Barr virus (EBV); Hantavirus; Hepatitis B Viruses (HBV); Hepatitis C Viruses (HCV); Herpes Simplex Virus (HSV); Kaposi’s sarcoma herpesvirus (KSHV); angiogenesis; therapeutics; vascular endothelial growth factor (VEGF); vascular endothelial growth factor receptor (VEGFR).

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
A schematic diagram summarizes how different viruses mediate vascular endothelial growth factor (VEGF) upregulation.
See this image and copyright information in PMC

References

    1. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003;9:669–676. doi: 10.1038/nm0603-669. - DOI - PubMed
    1. Evans I. An Overview of VEGF-Mediated Signal Transduction. Methods Mol. Biol. 2015;1332:91–120. - PubMed
    1. Koch S., Tugues S., Li X., Gualandi L., Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011;437:169–183. doi: 10.1042/BJ20110301. - DOI - PubMed
    1. Roskoski R.J. VEGF receptor protein-tyrosine kinases: Structure and regulation. Biochem. Biophys. Res. Commun. 2008;375:287–291. doi: 10.1016/j.bbrc.2008.07.121. - DOI - PubMed
    1. Kendall R.L., Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA. 1993;90:10705–10709. doi: 10.1073/pnas.90.22.10705. - DOI - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources